Sinan Sabit Kocabeyoglu

Sinan Sabit Kocabeyoglu

Auto-generated profile, based on publicly available information

Sinan Sabit Kocabeyoglu

Department of Cardiovascular Surgery, Ankara Bilkent City Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2018 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
EUErtekin Utku Unal
Ertekin Utku Unal
BDBurcu Demirkan
Burcu Demirkan
MPMustafa Pac
Mustafa Pac

15 October 2017 in Artificial Organs
Verified
Journal Article
Closed access
MPMustafa Pac
Mustafa Pac
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
SKSerhat Koca
Serhat Koca
FPFeyza Aysenur Pac
Feyza Aysenur Pac

1 June 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
MKMehmet Karahan
Mehmet Karahan
EAEmre Aygun
Emre Aygun
MPMustafa Pac
Mustafa Pac
OBJECTIVES: The aim of this study was to examine the haemodynamic effects of preoperative levosimendan infusion in patients who underwent left ventricular assist device implantation and evaluate the prognoses. METHODS: Between May 2013 and October 2018, 85 adult patients who underwent left ventricular assist device implantation were included; 44 and 41 patients suffered from dilated cardiomyopathy and ischaemic cardiomyopathy, respectively. Patients were divided into 2 groups: group A (58 patients) included those who received levosimendan infusion in addition to other inotropes and group B (27 patients) included those who received inotropic agents other than levosimendan. Levosimendan infusion was started at a dose of 0.1 µg⋅kg−1⋅min−1 for a maximum of 48 h without a bolus. The primary outcome was early right ventricular failure (RVF). The secondary outcomes were in-hospital mortality, need for right ventricular assist device, late RVF and recovery of end-organ functions. The safety end points of levosimendan included hypotension, atrial fibrillation, ventricular tachycardia or fibrillation and resuscitated cardiac arrest. RESULTS: Patient characteristics were similar in both groups. No significant differences between groups were observed in the rates of early mortality, RVF, need for right ventricular assist device, cardiopulmonary bypass time and intensive care unit stay. Survival rates at 30 days, 1 year and 3 years and freedom from late RVF were similar between the groups. Administration of levosimendan was safe, generally well-tolerated and not interrupted because of side effects. CONCLUSIONS: Levosimendan therapy was well-tolerated in patients who received permanent left ventricular assist devices. Combined preoperative therapy with inotropes and levosimendan significantly improves end-organ functions.

16 August 2020 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
DSDogan Emre Sert
Dogan Emre Sert
MKMehmet Karahan
Mehmet Karahan
EAEmre Aygun
Emre Aygun
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
MAMustafa Akdi
Mustafa Akdi
UKUmit Kervan
Umit Kervan

3 December 2019 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
MKMehmet Karahan
Mehmet Karahan
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
EAEmre Aygun
Emre Aygun
MPMustafa Pac
Mustafa Pac

1 April 2021 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
MKMehmet Karahan
Mehmet Karahan
EUErtekin Utku Unal
Ertekin Utku Unal
MPMustafa Pac
Mustafa Pac